A Pilot Study of A Novel Cognitive Intervention for Cancer Survivors
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm
- Sponsor
- University of California, San Francisco
- Enrollment
- 49
- Locations
- 1
- Primary Endpoint
- Mean changes in Adaptive Cognitive Evaluation (ACE)
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
This clinical trial investigates if certain electronic games may be effective in improving attention and memory function in cancer survivors. Cancer related cognitive impairment (CRCI) is an issue experienced by many cancer patients/survivors. CRCI includes perceived or objective problems with memory, executive function, and attention/concentration. CRCI has a negative impact on survivors' ability to work, carry out routine activities, and engage in social and family relationships. CRCI may result in significant distress and reduced quality of life. Certain electronic games may help improve attention and memory function in cancer survivors and reduce symptoms of CRCI.
Detailed Description
PRIMARY OBJECTIVES: I. Determine the recruitment and retention rates for both arms of this study. II. Determine the effect size for changes in cognitive function (i.e., Test of Variables of Attention (TOVA) \[i.e. attention\], Adaptive Cognitive Evaluation (ACE) \[i.e. working memory\]) in the intervention group compared to the control group following the 4-week study. III. Evaluate adherence rates for and satisfaction with the interventions. IV. Evaluate for treatment-related adverse events (e.g., nausea, motion sickness). SECONDARY OBJECTIVE: I. To determine effect sizes for depression, fatigue, and sleep disturbance, by comparing changes in the intervention group to changes in the control group, following the 4-week study. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients play Endeavor over 25 minutes daily 5 days a week for 4 weeks. ARM II: Patients play Words! over 25 minutes daily 5 days a week for 4 weeks.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Attention Function Index (AFI) score of \< 7.5
- •Are able to read, write, and understand English
- •Ability to understand an electronic informed consent document, and the willingness to sign it
- •Have a Karnofsky performance status (KPS) score of \>= 50
- •Have access to WiFi connection
Exclusion Criteria
- •Receiving active treatment for cancer recurrence
- •Have significant cognitive impairment
- •Have sensory or motor deficits that prevent them from doing the assessment and using the application
Outcomes
Primary Outcomes
Mean changes in Adaptive Cognitive Evaluation (ACE)
Time Frame: Up to 4 weeks
The ACE is a mobile cognitive control assessment battery containing standard tests that assess different aspects of cognitive control (attention, working memory, and goal management), modified by incorporating adaptive algorithms, immersive graphics, video tutorials, motivating feedback, and a user-friendly interface. The ACE is administered to all participants via iPad and the scores will be estimated as the standardized difference in means from enrollment (Week 1) to the last assessment (Week 4).
Proportion of time using application
Time Frame: Up to 4 weeks
Adherence rate will be evaluated by comparing the amount of time the participant should have used the application to the actual amount of time the participant used the application.
Percentage of participants who completed the study
Time Frame: Up to 6 weeks
Completion is defined as participants who completed all 4 weeks of intervention and final assessment.
Percent change in scores on the TOVA over time
Time Frame: Up to 4 weeks
The TOVA records responses to visual or auditory stimuli through the participants iPAD, with a unique, highly accurate +/1 millisecond (ms) microswitch. The TOVA (Copyright 1991- 2021 by The TOVA Company) automatically calculates response time variability (consistency), response time (speed), commissions (impulsivity), and omissions (focus and vigilance). Results are reported as standard scores (average = 100 with a standard deviation of 15) and are compared to a large normative sample stratified by gender and age. Scores above 85 are within normal limits, 80-85 are borderline, and below 80 are not within normal limits. Will be estimated as the standardized difference between the groups in the percent score change from enrollment (Week 1) to the last assessment (Week 4).
Mean change in scores on the Test of Variables of Attention (TOVA) over time
Time Frame: Up to 4 weeks
The TOVA records responses to visual or auditory stimuli through the participants iPAD, with a unique, highly accurate +/1 millisecond (ms) microswitch. The TOVA (Copyright 1991- 2021 by The TOVA Company) automatically calculates response time variability (consistency), response time (speed), commissions (impulsivity), and omissions (focus and vigilance). Results are reported as standard scores (average = 100 with a standard deviation of 15) and are compared to a large normative sample stratified by gender and age. Scores above 85 are within normal limits, 80-85 are borderline, and below 80 are not within normal limits. The mean change in scores will be estimated as the norm-based standardized difference in means from enrollment (Week 1) to the last assessment (Week 4).
Percent change in scores on the ACE over time
Time Frame: Up to 4 weeks
The ACE is a mobile cognitive control assessment battery containing standard tests that assess different aspects of cognitive control (attention, working memory, and goal management), modified by incorporating adaptive algorithms, immersive graphics, video tutorials, motivating feedback, and a user-friendly interface. The ACE is administered to all participants via iPad and the scores will be estimated as the standardized difference between the groups in the percent score change from enrollment (Week 1) to the last assessment (Week 4).
Percentage of participants who experienced treatment-related adverse events
Time Frame: Up to 6 weeks
Safety analyses will involve examination of and comparison between groups for the percentage of participants by adverse event severity and type of treatment-related adverse events. Comparisons of the frequencies between groups will be conducted using Chi-square or Fisher's exact test.
Secondary Outcomes
- Change in mean severity scores on the Lee Fatigue Scale(Up to 4 weeks)
- Change in mean severity scores on the Center for Epidemiologic Studies - Depression Scale (CES-D)(Up to 4 weeks)
- Change in severity scores on the General Sleep Disturbance Scale (GSDS)(Up to 4 weeks)